Literature DB >> 3024033

The positive inotropic response to milrinone in isolated human and guinea pig myocardium.

L Brown, M Näbauer, E Erdmann.   

Abstract

The bipyridine derivative, milrinone, produced positive inotropic effects in isolated, contracting right ventricular papillary muscles and left atria from guinea pigs as well as in human papillary muscle strips. The inotropic effect was biphasic in guinea pig papillary muscles (EC50, high affinity, 1.5 X 10(-6) mol/l, about 35% of maximal effect; apparent EC50, 3 X 10(-5) mol/l with a maximal effect at 2 X 10(-4) mol/l) but monophasic in guinea pig left atria (EC50, 6 X 10(-5) mol/l) and in human papillary muscle strips (EC50, 5.8 X 10(-5) mol/l). In guinea pig papillary muscles, reserpine pretreatment or l-practolol preincubation reduced the low concentration effect only. In the presence of l-practolol, carbachol reduced the low concentration effect only. In the presence of l-practolol, carbachol reduced but not abolished the inotropic effects of milrinone (3 X 10(-6) mol/l, 1 X 10(-4) mol/l) in both guinea pig and human myocardium. This antagonism was prevented by atropine preincubation. The maximum inotropic effect of milrinone was similar to that of ouabain and calcium in guinea pig myocardium but markedly less than either calcium or ouabain in human myocardium. Milrinone inhibited crude guinea pig and human cardiac phosphodiesterase activity in vitro but did not inhibit 3H-ouabain binding to partially purified human cardiac (Na+ + K+)-ATPase-containing membranes. We conclude that the primary mode of action of milrinone in both guinea pig and human myocardium is through inhibition of phosphodiesterase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024033     DOI: 10.1007/bf00505822

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  32 in total

Review 1.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

2.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  Phosphodiesterase-inhibiting properties of newer inotropic agents.

Authors:  H Scholz; W Meyer
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

4.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

5.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

6.  Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.

Authors:  D S Baim; A V McDowell; J Cherniles; E S Monrad; J A Parker; J Edelson; E Braunwald; W Grossman
Journal:  N Engl J Med       Date:  1983-09-29       Impact factor: 91.245

7.  Inotropic and vasodilator effects of amrinone on isolated human tissue.

Authors:  P T Wilmshurst; J M Walker; C H Fry; J P Mounsey; C H Twort; B T Williams; M J Davies; M M Webb-Peploe
Journal:  Cardiovasc Res       Date:  1984-05       Impact factor: 10.787

8.  Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals.

Authors:  A A Alousi; J M Canter; M J Montenaro; D J Fort; R A Ferrari
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

Review 9.  Inotropic drugs and their mechanisms of action.

Authors:  H Scholz
Journal:  J Am Coll Cardiol       Date:  1984-08       Impact factor: 24.094

10.  Responses to amrinone in isolated cardiac muscles from cat, rabbit, and guinea pig.

Authors:  P K Siegl; G Morgan; C S Sweet
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

View more
  7 in total

1.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Involvement of purine compounds in the inotropic action of milrinone.

Authors:  P Dorigo; R M Gaion; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 3.  The effectiveness of inotropic agents in isolated cardiac preparations from the human heart.

Authors:  E Erdmann
Journal:  Klin Wochenschr       Date:  1988-01-04

Review 4.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

5.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

6.  Reduced alpha 1- and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure.

Authors:  M Steinfath; W Danielsen; H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; T Reich; W Schmitz; H Scholz
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

7.  Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes.

Authors:  Najah Abi-Gerges; Tim Indersmitten; Ky Truong; William Nguyen; Phachareeya Ratchada; Nathalie Nguyen; Guy Page; Paul E Miller; Andre Ghetti
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.